QNRX QUOIN PHARMACEUTICALS LTD Product Launches 8-K Filing 2025 - Clinical Data Update Quoin Pharmaceuticals announced positive interim clinical data from a study on QRX003 for Netherton Syndrome, showing significant improvements in skin symptoms and itch severity after 12 weeks of treatment, with no safety concerns reported.Get access to all SEC 8-K filings of the QUOIN PHARMACEUTICALS LTD